Bryce Point Capital, LLC Viking Therapeutics, Inc. Transaction History
Bryce Point Capital, LLC
- $81.9 Billion
- Q3 2025
A detailed history of Bryce Point Capital, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Bryce Point Capital, LLC holds 11,612 shares of VKTX stock, worth $462,157. This represents 0.37% of its overall portfolio holdings.
Number of Shares
11,612
Previous 18,840
38.37%
Holding current value
$462,157
Previous $499 Million
38.88%
% of portfolio
0.37%
Previous 0.42%
Shares
2 transactions
Others Institutions Holding VKTX
# of Institutions
449Shares Held
67.2MCall Options Held
7.12MPut Options Held
3.46M-
Vanguard Group Inc Valley Forge, PA10MShares$398 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$240 Million0.01% of portfolio
-
State Street Corp Boston, MA4.51MShares$180 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.73MShares$148 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.58MShares$103 Million0.0% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $3.05B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...